Akero Heads To Top Of FGF21 Class In NASH; Genfit Says Pandemic Won’t Delay Phase III

 
• By Joseph Haas
  
Human Liver Anatomy. 3D
Akero has data showing its FGF21 analog can reduce hepatic fat; now it hopes to see a fibrosis benefit in NASH patients

More from Clinical Trials

More from R&D